, /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: ) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual meeting of holders of common shares ("Shareholders") held on (the "Meeting"). The voting results for each of the matters presented at the Meeting are outlined below.
There were 337 Shareholders represented virtually or by proxy at the Meeting holding 59,605,486 common shares, representing 14.72% of MediPharm Labs' total issued and outstanding common shares as at the record date for the Meeting. As the Meeting was held virtually, all resolutions were passed by a ballot vote.
Each of the nominees for election as directors were elected as directors of MediPharm Labs for the ensuing year or until their successors are elected or appointed. Voting results for the election of the individual directors are as set out below: The Company's Board of Directors continues to be composed almost entirely of Independent Directors, with being the only Executive Director. MNP LLP, Chartered Professional Accountants, was appointed as auditor of MediPharm Labs until the next annual meeting of the holders of the Shareholders at remuneration to be fixed by the directors.
Voting results are as set out below: Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active p.
